New publication: Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database

Abstract

 

Background:

The optimal interval for repeat biopsy during active surveillance (AS) for prostate cancer is yet to be defined. This study examined whether risk of up-grading (to grade group2) or risk of converting to treatment varied according to intensity of repeat biopsy using data from the GAP3 consortium’s global AS database.

 

Materials and Methods:

Intensity of surveillance biopsy schedules was categorized according to centersprotocols: (a) Prostate Cancer Research International Active Surveillance project (PRIAS) protocols with biopsies at years 1, 4,and 7 (10 centers; 7532 men); (b) biennial biopsies, that is, every other year (8 centers; 4365 men); and (c) annual biopsy schedules (4 centers; 1602 men). Multivariable Cox regression was used to compare outcomes according to biopsy intensity.

 

Results:

Out of the 13,508 eligible participants, 56% were managed according to PRIAS protocols (biopsies at years 1, 4, and 7), 32% via biennial biopsy, and 12% via annual biopsy. After adjusting for baseline characteristics, risk of converting to treatment was greater for those on annual compared with PRIAS biopsy schedules (hazard ratio [HR] = 1.66; 95% confidence interval [CI] = 1.51–1.83;p< 0.001), while risk of upgrading did not differ (HR = 0.96; 95% CI = 0.84–1.10).

 

Conclusion:

Results suggest more frequent biopsy schedules may deter some men from continuing AS despite no evidence of grade progression.

 

Reference article:

Beckmann KR, Bangma CH, Helleman J, Bjartell A, Carroll PR, Morgan T, Nieboer D, Santaolalla A, Trock BJ, Valdagni R, Roobol MJ; Global Action Plan Active Surveillance Prostate Cancer [G.A.P.3] Consortium. Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database. Prostate. 2022 PMID: 35254666.

Link: http://doi.org/10.1002/pros.24330

Mar 8, 2022